Work

Abstract PS3-09-08: Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps3-09-08

Authors: S. Hurvitz, M. Jarzab, A. Ring, P. Sharma, I. Temciuc, H. Hu, M. Akdere, J. Pablo Zarate, D. Yardley

Institutions: University of Washington, The Maria Sklodowska-Curie National Research Institute of Oncology, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of Kansas Medical Center, Translational Research in Oncology, Novartis (Switzerland), Sarah Cannon

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129780827

Cites:

Cited by:

Related to: